Strategies to functionalize extracellular vesicles against HER2 for anticancer activity

Abstract

Cell-secreted extracellular vesicles (EVs) are membranous particles highly heterogeneous in size and molecular cargo. Comprehensively, released EV sub-populations can show a wide range and selection of different protein, RNA, and lipid species, complementing cell communication signals. Recently, EVs represent a new source for developing targeted delivery systems. EVs are stable in biofluids, intrinsically biocompatible with low immunogenicity, and capable of transferring cargo molecules into “recipient” cells. The immune-mediated recognition represents a popular approach to functionalize and direct EVs towards receptor-positive cell populations. The human epidermal growth factor receptor 2 (HER2, also known as neu or ERBB2) is a tyrosine kinase of clinical relevance, targeted by several available antibodies, and a model receptor used to test the biodistribution and anticancer activity of bioformulations, including EVs. Here, we focus on recent strategies adopted for EV functionalization with fusion ligands able to recognize HER2, covering the enhanced expression of membrane-fusion proteins in “EV-donor” cells as well as post-isolation EV-surface modifications.

Keywords

Extracellular vesicles / human epidermal growth factor receptor 2 (HER2/ERBB2) / EV engineering / fusion proteins

References

[1] Herrmann IK,Fuhrmann G.Extracellular vesicles as a next-generation drug delivery platform.Nat Nanotechnol2021;16:748-59

[2] Duncan R.Endocytosis and intracellular trafficking as gateways for nanomedicine delivery: opportunities and challenges.Mol Pharm2012;9:2380-402

[3] Niel G, D’Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles.Nat Rev Mol Cell Biol2018;19:213-28

[4] Doyle LM.Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis.Cells2019;8:727 PMCID:PMC6678302

[5] Fabbiano F,Gurrieri E,Notarangelo M.RNA packaging into extracellular vesicles: an orchestra of RNA-binding proteins?.J Extracell Vesicles2020;10:e12043 PMCID:PMC7769857

[6] Sork H,Krjutskov K.Heterogeneity and interplay of the extracellular vesicle small RNA transcriptome and proteome.Sci Rep2018;8:10813 PMCID:PMC6050237

[7] Andaloussi S, Mäger I, Breakefield XO, Wood MJ. Extracellular vesicles: biology and emerging therapeutic opportunities.Nat Rev Drug Discov2013;12:347-57

[8] Kim OY,Gho YS.Extracellular vesicle mimetics: novel alternatives to extracellular vesicle-based theranostics, drug delivery, and vaccines.Semin Cell Dev Biol2017;67:74-82

[9] Wang Y,Tian B.Nucleolin-targeted extracellular vesicles as a versatile platform for biologics delivery to breast cancer.Theranostics2017;7:1360-72 PMCID:PMC5399599

[10] Munir J,Ryu S.Therapeutic miRNA-Enriched extracellular vesicles: current approaches and future prospects.Cells2020;9:2271 PMCID:PMC7601381

[11] O'Brien K,Ughetto S,Breakefield XO.RNA delivery by extracellular vesicles in mammalian cells and its applications.Nat Rev Mol Cell Biol2020;21:585-606 PMCID:PMC7249041

[12] Ohno S,Sudo K.Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells.Mol Ther2013;21:185-91 PMCID:PMC3538304

[13] Nuti M,Visconti V.Immune effects of trastuzumab.J Cancer2011;2:317-23 PMCID:PMC3119394

[14] Ahn S,Lee K.HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation.J Pathol Transl Med2020;54:34-44 PMCID:PMC6986968

[15] Iqbal N.Human epidermal growth factor receptor 2 (her2) in cancers: overexpression and therapeutic implications.Mol Biol Int2014;2014:852748 PMCID:PMC4170925

[16] Ooi A,Li X.Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study.Mod Pathol2004;17:895-904

[17] Nanou A,Bidard FC,Terstappen LWMM.HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer.Breast Cancer Res2020;22:86 PMCID:PMC7424685

[18] Kim D,Lee C.EV-Ident: Identifying tumor-specific extracellular vesicles by size fractionation and single-vesicle analysis.Anal Chem2020;92:6010-8

[19] Jiang Q,Wang L,Zhong W.Rapid enrichment and detection of extracellular vesicles enabled by CuS-enclosed microgels.Anal Chem2019;91:15951-8 PMCID:PMC7417204

[20] Ciravolo V,Ghedini GC.Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy.J Cell Physiol2012;227:658-67

[21] Quinn Z,Xia Y,Wan Y.Conferring receptors on recipient cells with extracellular vesicles for targeted drug delivery.Bioact Mater2021;6:749-56 PMCID:PMC7522541

[22] Salimi F,Rajabibazl M.Development of a novel anti-HER2 scFv by ribosome display and in silico evaluation of its 3D structure and interaction with HER2, alone and after fusion to LAMP2B.Mol Biol Rep2018;45:2247-56

[23] Krop I.Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.Clin Cancer Res2014;20:15-20

[24] Xu Z,Jiang Z.Novel HER2-targeting antibody-drug conjugates of trastuzumab beyond T-DM1 in breast cancer: trastuzumab deruxtecan(DS-8201a) and (Vic-)trastuzumab duocarmazine (SYD985).Eur J Med Chem2019;183:111682

[25] Gajria D.HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.Expert Rev Anticancer Ther2011;11:263-75 PMCID:PMC3092522

[26] Kirpotin D,Hong K.Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.Biochemistry1997;36:66-75

[27] Van de Broek B,D’Hollander A.Specific cell targeting with nanobody conjugated branched gold nanoparticles for photothermal therapy.ACS Nano2011;5:4319-28

[28] Florczak A,Kucharczyk K.Systemic and local silk-based drug delivery systems for cancer therapy.Cancers (Basel)2021;13:5389 PMCID:PMC8582423

[29] Aharon A,Bar-Lev TH.Extracellular vesicles derived from chimeric antigen receptor-T cells: a potential therapy for cancer.Hum Gene Ther2021;32:1224-41

[30] Zhao C,Vershel CP.Multifunctional transmembrane protein ligands for cell-specific targeting of plasma membrane-derived vesicles.Small2016;12:3837-48 PMCID:PMC5523125

[31] Limoni SK,Moazzeni SM,Salimi F.Engineered exosomes for targeted transfer of siRNA to HER2 positive breast cancer cells.Appl Biochem Biotechnol2019;187:352-64

[32] Gomari H,Soleimani M,Khodashenas S.Targeted delivery of doxorubicin to HER2 positive tumor models.IJN2019;14:5679-90. PMCID:PMC6662522

[33] Molavipordanjani S,Abedi SM,Mardanshahi A.^99mTc-radiolabeled HER2 targeted exosome for tumor imaging.Eur J Pharm Sci2020;148:105312

[34] Liang G,Ali DJ.Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer.J Nanobiotechnology2020;18:10 PMCID:PMC6950820

[35] Shi X,Hou T.Genetically engineered cell-derived nanoparticles for targeted breast cancer immunotherapy.Mol Ther2020;28:536-47 PMCID:PMC7001084

[36] Longatti A,Collinson A.High affinity single-chain variable fragments are specific and versatile targeting motifs for extracellular vesicles.Nanoscale2018;10:14230-44

[37] Wang L,Zou W.Exosomes containing miRNAs targeting HER2 synthesis and engineered to adhere to HER2 on tumor cells surface exhibit enhanced antitumor activity.J Nanobiotechnology2020;18:153 PMCID:PMC7592554

[38] Forterre AV,Delcayre A.Extracellular vesicle-mediated.in vitro19:858-67 PMCID:PMC7056535

[39] Kooijmans SAA,van der Meel R.PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time.J Control Release2016;224:77-85

[40] Kooijmans SAA,Schiffelers RM.Recombinant phosphatidylserine-binding nanobodies for targeting of extracellular vesicles to tumor cells: a plug-and-play approach.Nanoscale2018;10:2413-26 PMCID:PMC5795695

[41] Wang JH,Zhao J.Anti-HER2 scFv-Directed extracellular vesicle-mediated mRNA-based gene delivery inhibits growth of HER2-positive human breast tumor xenografts by prodrug activation.Mol Cancer Ther2018;17:1133-42 PMCID:PMC5932266

[42] Li C,Hu Z.Natural single-domain antibody-nanobody: a novel concept in the antibody field.J Biomed Nanotechnol2018;14:1-19

[43] Pham TC,Pham TT.Covalent conjugation of extracellular vesicles with peptides and nanobodies for targeted therapeutic delivery.J Extracell Vesicles2021;10:e12057 PMCID:PMC7886705

[44] Sato YT,Sawada S.Engineering hybrid exosomes by membrane fusion with liposomes.Sci Rep2016;6:21933 PMCID:PMC4766490

[45] Barok M,Vereb G,Isola J.Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation.BMC Cancer2018;18:504 PMCID:PMC5930687

[46] Nahta R,Hung MC,Esteva FJ.Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.Nat Clin Pract Oncol2006;3:269-80

[47] Wu Y,Klinke DJ 2nd.Exosomes: improved methods to characterize their morphology, RNA content, and surface protein biomarkers.Analyst2015;140:6631-42 PMCID:PMC4986832

[48] Staufer O,Rimal R.Bottom-up assembly of biomedical relevant fully synthetic extracellular vesicles.Sci Adv2021;7:eabg6666 PMCID:PMC8442894